Valuation

CGENCompugen

StockNasdaqIsraelHealth careEU retail investors: available

−2.3% today · +25.1% over a year

8/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 86% of the instruments we score

Quality: among the best of its peers; priced lower than most peers. No dividend.

Compugen (CGEN) valuation against sector peers: P/E 5.6 (sector median 25.7), P/B 1.9, EV/EBIT 3.1, free-cash-flow yield 15.9%, P/S 2.7.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricCGENSector medianvs median
P/E5.625.7 · n=2678% below
P/B1.93.6 · n=4547% below
P/S2.74.7 · n=4042% below
EV/EBIT3.122.6 · n=2886% below
Free-cash-flow yield15.9%3.8% · n=39322% above
Dividend yield0.00%0.19% · n=99100% below
Return on equity44.8%5.2% · n=56761% above
Return on invested capital128.1%6.5% · n=471,879% above
Gross margin87.3%70.2% · n=3924% above
Net debt / EBITDA−3.142.08 · n=25251% below

Value factor: 89 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

NOVNNovartis AG22.46.818.75.6%2.8%10/10
NVSNovartis AG22.36.818.75.6%2.4%10/10
AZNAstraZeneca PLC28.35.922.84.1%1.2%5/10
AZNAstraZeneca plc28.35.922.84.1%1.7%6/10
NVONovo Nordisk A/S11.86.210.34.9%4.6%7/10
SNYSanofi13.41.518.26.9%4.3%7/10
SANSanofi SA13.41.518.26.9%4.8%9/10
GSKGSK plc14.55.111.87.7%3.5%9/10
TEVATeva Pharmaceutical Industries Limited97.86.243.32.5%0.0%6/10
ALCAlcon AG37.51.729.34.7%0.5%5/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 31 Dec 2025 · filed 02 Mar 2026